(Circulation. 1999;99:552-557.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Inhibition of P-Glycoprotein–Mediated Drug Transport
A Unifying Mechanism to Explain the Interaction Between Digoxin and Quinidine
From the Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.
Correspondence to Dan M. Roden, MD, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6602. E-mail dan.roden{at}mcmail.vanderbilt.edu
Background—Although quinidine is known to elevate plasma digoxin concentrations, the mechanism underlying this interaction is not fully understood. Digoxin is not extensively metabolized, but it is known to be transported by the drug efflux pump P-glycoprotein, which is expressed in excretory tissues (kidney, liver, intestine) and at the blood-brain barrier. Accordingly, we tested the hypothesis that inhibition of P-glycoprotein–mediated digoxin transport by quinidine contributes to the digoxin-quinidine interaction.
Methods and Results—First, we demonstrated active transcellular transport of both digoxin and quinidine in cultured cell lines that express P-glycoprotein in a polarized fashion. In addition, 5 µmol/L quinidine inhibited P-glycoprotein–mediated digoxin transport by 57%. Second, the effect of quinidine on digoxin disposition was studied in wild-type and in mdr1a(-/-) mice, in which the gene expressing the major digoxin-transporting P-glycoprotein has been disrupted. Because the in vitro data showed that quinidine itself is a P-glycoprotein substrate, quinidine doses were reduced in mdr1a(-/-) mice to produce plasma concentrations similar to those in wild-type control animals. Quinidine increased plasma digoxin concentrations by 73.0% (P=0.05) in wild-type animals, compared with 19.5% (P=NS) in mdr1a(-/-) mice. Moreover, quinidine increased digoxin brain concentrations by 73.2% (P=0.05) in wild-type animals; by contrast, quinidine did not increase digoxin brain concentrations in mdr1a(-/-) mice but rather decreased them (-30.7%, P<0.01).
Conclusions—Quinidine and digoxin are both substrates for P-glycoprotein, and quinidine is a potent inhibitor of digoxin transport in vitro. The in vivo data strongly support the hypothesis that inhibition of P-glycoprotein–mediated digoxin elimination plays an important role in the increase of plasma digoxin concentration occurring with quinidine coadministration in wild-type mice and thus support a similar mechanism in humans.
Key Words: antiarrhythmia agents • brain • drugs • pharmacology • P-glycoprotein
This article has been cited by other articles:
 |
|
 |
|
  J. M. A. Delou, A. G. Lopes, and M. A.M. Capella Unveiling the Role of Multidrug Resistance Proteins in Hypertension Hypertension, August 1, 2009; 54(2): 210 - 216. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden and C. M. Stein Clopidogrel and the Concept of High-Risk Pharmacokinetics Circulation, April 28, 2009; 119(16): 2127 - 2130. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bachmakov, H. Glaeser, M. F. Fromm, and J. Konig Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1 Diabetes, June 1, 2008; 57(6): 1463 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kitamura, H. Koto, S. Matsuura, T. Kawabata, H. Tsuchiya, H. Kusuhara, H. Tsujimoto, and Y. Sugiyama Modest Effect of Impaired P-glycoprotein on the Plasma Concentrations of Fexofenadine, Quinidine, and Loperamide following Oral Administration in Collies Drug Metab. Dispos., May 1, 2008; 36(5): 807 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. He, R. Sabo, G. Sunkara, M.-N. Bizot, G.-J. Riviere, S. Leon, M. Ligueros-Saylan, W. P. Dole, and D. Howard Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers J. Clin. Pharmacol., August 1, 2007; 47(8): 998 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Ghanem, P. C. Gomez, M. C. Arana, M. Perassolo, G. D. Carpini, M. G. Luquita, L. M. Veggi, V. A. Catania, L. A. Bengochea, and A. D. Mottino Induction of Rat Intestinal P-glycoprotein by Spironolactone and Its Effect on Absorption of Orally Administered Digoxin J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1146 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rautio, J. E. Humphreys, L. O. Webster, A. Balakrishnan, J. P. Keogh, J. R. Kunta, C. J. Serabjit-Singh, and J. W. Polli IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES Drug Metab. Dispos., May 1, 2006; 34(5): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nishio, T. Katsura, K. Ashida, M. Okuda, and K.-i. Inui MODULATION OF P-GLYCOPROTEIN EXPRESSION IN HYPERTHYROID RAT TISSUES Drug Metab. Dispos., November 1, 2005; 33(11): 1584 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, E. Mak, R. G. Tirona, E. Tan, P. M. Novikoff, P. Wang, A. W. Wolkoff, and K. S. Pang Vascular Binding, Blood Flow, Transporter, and Enzyme Interactions on the Processing of Digoxin in Rat Liver J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 433 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesis Cardiovasc Res, August 15, 2005; 67(3): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Beringer and R. L Slaughter Transporters and Their Impact on Drug Disposition Ann. Pharmacother., June 1, 2005; 39(6): 1097 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Hoffmaster, M. J. Zamek-Gliszczynski, G. M. Pollack, and K. L. R. Brouwer MULTIPLE TRANSPORT SYSTEMS MEDIATE THE HEPATIC UPTAKE AND BILIARY EXCRETION OF THE METABOLICALLY STABLE OPIOID PEPTIDE [D-PENICILLAMINE2,5]ENKEPHALIN Drug Metab. Dispos., February 1, 2005; 33(2): 287 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Pope, M. H. Khalil, J. E. Berg, M. Stiles, G. J. Yakatan, and E. M. Sellers Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers J. Clin. Pharmacol., October 1, 2004; 44(10): 1132 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Sarich, K.-M. Schutzer, M. Wollbratt, U. Wall, E. Kessler, and U. G. Eriksson No Pharmacokinetic or Pharmacodynamic Interaction Between Digoxin and the Oral Direct Thrombin Inhibitor Ximelagatran in Healthy Volunteers J. Clin. Pharmacol., August 1, 2004; 44(8): 935 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-L. Tsai and T.-H. Tsai HEPATOBILIARY EXCRETION OF BERBERINE Drug Metab. Dispos., April 1, 2004; 32(4): 405 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Lau, C.-Y. Wu, H. Okochi, and L. Z. Benet Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1040 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, M. Tu, R. S. Kelly, C. Chen, and B. J. Smith DEVELOPMENT OF A COMPUTATIONAL APPROACH TO PREDICT BLOOD-BRAIN BARRIER PERMEABILITY Drug Metab. Dispos., January 1, 2004; 32(1): 132 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Roden Cardiovascular Pharmacogenomics Circulation, December 23, 2003; 108(25): 3071 - 3074. [Full Text] [PDF]
|
|
|
|
|
|
S. Dallas, X. Zhu, S. Baruchel, L. Schlichter, and R. Bendayan Functional Expression of the Multidrug Resistance Protein 1 in Microglia J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 282 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Feuring, Y. Lee, L. H. Orlowski, N. Michiels, M. De Smet, A. K. Majumdar, K. J. Petty, M. R. Goldberg, M. G. Murphy, K. M. Gottesdiener, et al. Lack of Effect of Aprepitant on Digoxin Pharmacokinetics in Healthy Subjects J. Clin. Pharmacol., August 1, 2003; 43(8): 912 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Williams Clinical decision making on statin drug interactions J. Am. Coll. Cardiol., July 16, 2003; 42(2): 396 - 397. [Full Text] [PDF]
|
|
|
|
|
|
S. Zhang and M. E. Morris Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1258 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hitzl, K. Klein, U. M. Zanger, P. Fritz, A. K. Nussler, P. Neuhaus, and M. F. Fromm Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 524 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Ronaldson and R. Bendayan Renal Drug Transport and Drug-Drug Interactions Journal of Pharmacy Practice, December 1, 2002; 15(6): 490 - 503. [Abstract] [PDF]
|
|
|
|
 |
|
 A. K. Angirasa and A. Z. Koch P-glycoprotein as the Mediator of Itraconazole-Digoxin Interaction J Am Podiatr Med Assoc, September 1, 2002; 92(8): 471 - 472. [Full Text] [PDF]
|
|
|
|
|
|
R. K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S. K. Gupta, and M. F. Fromm Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4 J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 645 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lee, L. Schlichter, M. Bendayan, and R. Bendayan Functional Expression of P-glycoprotein in Rat Brain Microglia J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Smith, A. C. Doran, S. McLean, F. D. Tingley III, B. T. O'Neill, and S. M. Kajiji P-Glycoprotein Efflux at the Blood-Brain Barrier Mediates Differences in Brain Disposition and Pharmacodynamics between Two Structurally Related Neurokinin-1 Receptor Antagonists J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1252 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.L. Bauman The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K93 - K100. [Abstract] [PDF]
|
|
|
|
|
|
E. V. Batrakova, D. W. Miller, S. Li, V. Y. Alakhov, A. V. Kabanov, and W. F. Elmquist Pluronic P85 Enhances the Delivery of Digoxin to the Brain: In Vitro and in Vivo Studies J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 551 - 557. [Abstract] [Full Text]
|
|
|
|
|
|
R. H. Stephens, C. A. O'Neill, A. Warhurst, G. L. Carlson, M. Rowland, and G. Warhurst Kinetic Profiling of P-glycoprotein-Mediated Drug Efflux in Rat and Human Intestinal Epithelia J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 584 - 591. [Abstract] [Full Text]
|
|
|
|
|
|
M. Yamazaki, W. E. Neway, T. Ohe, I-W. Chen, J. F. Rowe, J. H. Hochman, M. Chiba, and J. H. Lin In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 723 - 735. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. F. Fromm, H.-M. Kauffmann, P. Fritz, O. Burk, H. K. Kroemer, R. W. Warzok, M. Eichelbaum, W. Siegmund, and D. Schrenk The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters Am. J. Pathol., November 1, 2000; 157(5): 1575 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M Roden ELECTROPHYSIOLOGY: Antiarrhythmic drugs: from mechanisms to clinical practice Heart, September 1, 2000; 84(3): 339 - 346. [Full Text] [PDF]
|
|
|
|
|
|
C. Wandel, R. B. Kim, F. P. Guengerich, and A. J. J. Wood Mibefradil Is a P-Glycoprotein Substrate and a Potent Inhibitor of Both P-Glycoprotein and CYP3A In Vitro Drug Metab. Dispos., August 1, 2000; 28(8): 895 - 898. [Abstract] [Full Text]
|
|
|
|
|
|
C. Pauli-Magnus, O. von Richter, O. Burk, A. Ziegler, T. Mettang, M. Eichelbaum, and M. F. Fromm Characterization of the Major Metabolites of Verapamil as Substrates and Inhibitors of P-glycoprotein J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 376 - 382. [Abstract] [Full Text]
|
|
|
|
|
|
D. R. Abernethy and D. A. Flockhart Molecular Basis of Cardiovascular Drug Metabolism : Implications for Predicting Clinically Important Drug Interactions Circulation, April 11, 2000; 101(14): 1749 - 1753. [Full Text] [PDF]
|
|
|
|
|
|
R. B. Kim, B. Leake, M. Cvetkovic, M. M. Roden, J. Nadeau, A. Walubo, and G. R. Wilkinson Modulation by Drugs of Human Hepatic Sodium-Dependent Bile Acid Transporter (Sodium Taurocholate Cotransporting Polypeptide) Activity J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1204 - 1209. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Herman Drug interactions and the statins Can. Med. Assoc. J., November 1, 1999; 161(10): 1281 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cvetkovic, B. Leake, M. F. Fromm, G. R. Wilkinson, and R. B. Kim OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine Drug Metab. Dispos., August 1, 1999; 27(8): 866 - 871. [Abstract] [Full Text]
|
|
|
|
|
|
M. F. Fromm, D. Darbar, S. Dell'Orto, and D. M. Roden Modulation of Effect of Dietary Salt on Prehepatic First-Pass Metabolism: Effects of beta -Blockade and Intravenous Salt Loading J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 253 - 258. [Abstract] [Full Text]
|
|
|
|
|
|
I. Rodriguez, D. R. Abernethy, and R. L. Woosley P-Glycoprotein in Clinical Cardiology Circulation, February 2, 1999; 99(4): 472 - 474. [Full Text] [PDF]
|
|